Literature DB >> 22203766

Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.

Michael F Press, Michael A Gordon, Dennis J Slamon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203766      PMCID： PMC3269964          DOI： 10.1200/JCO.2011.35.1023

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.

Authors:  Dennis J Slamon; Michael F Press
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

2.  Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.

Authors:  David Loesch; F Anthony Greco; Neil N Senzer; Howard A Burris; John D Hainsworth; Stephen Jones; Svetislava J Vukelja; John Sandbach; Frankie Holmes; Scot Sedlacek; John Pippen; Deborah Lindquist; Kristi McIntyre; Joanne L Blum; Manuel R Modiano; Kristi A Boehm; Feng Zhan; Lina Asmar; Nicholas Robert
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?

Authors:  Kathleen I Pritchard
Journal:  Oncologist       Date:  2009-10-09

4.  In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Authors:  Klaus P Hoeflich; Carol O'Brien; Zachary Boyd; Guy Cavet; Steve Guerrero; Kenneth Jung; Tom Januario; Heidi Savage; Elizabeth Punnoose; Tom Truong; Wei Zhou; Leanne Berry; Lesley Murray; Lukas Amler; Marcia Belvin; Lori S Friedman; Mark R Lackner
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

5.  HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

Authors:  Maurice P H M Jansen; Anieta M Sieuwerts; Maxime P Look; Kirsten Ritstier; Marion E Meijer-van Gelder; Iris L van Staveren; Jan G M Klijn; John A Foekens; Els M J J Berns
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

6.  Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.

Authors:  Gottfried E Konecny; Giovanni Pauletti; Michael Untch; He-Jing Wang; Volker Möbus; Walther Kuhn; Christoph Thomssen; Nadia Harbeck; Ling Wang; Sophia Apple; Fritz Jänicke; Dennis J Slamon
Journal:  Breast Cancer Res Treat       Date:  2010-02-04       Impact factor: 4.872

7.  Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

Authors:  F P O'Malley; S Chia; D Tu; L E Shepherd; M N Levine; V H Bramwell; I L Andrulis; K I Pritchard
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

8.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

Authors:  Stephen Jones; Frankie Ann Holmes; Joyce O'Shaughnessy; Joanne L Blum; Svetislava J Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert L Kirby; John Sandbach; William J Hyman; Donald A Richards; Robert G Mennel; Kristi A Boehm; Wally G Meyer; Lina Asmar; Daniel Mackey; Stefan Riedel; Hyman Muss; Michael A Savin
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

9.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Authors:  Pierre Farmer; Hervé Bonnefoi; Pascale Anderle; David Cameron; Pratyaksha Wirapati; Pratyakasha Wirapati; Véronique Becette; Sylvie André; Martine Piccart; Mario Campone; Etienne Brain; Gaëtan Macgrogan; Thierry Petit; Jacek Jassem; Frédéric Bibeau; Emmanuel Blot; Jan Bogaerts; Michel Aguet; Jonas Bergh; Richard Iggo; Mauro Delorenzi
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440

10.  Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Authors:  Edurne Arriola; Socorro Maria Rodriguez-Pinilla; Maryou B K Lambros; Robin L Jones; Michelle James; Kay Savage; Ian E Smith; Mitch Dowsett; Jorge S Reis-Filho
Journal:  Breast Cancer Res Treat       Date:  2007-01-27       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.